Marinus Pharmaceuticals (MRNS)
(Delayed Data from NSDQ)
$1.30 USD
-0.02 (-1.52%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.30 USD
-0.02 (-1.52%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Zacks News
5 Disruptive Biotech Stocks With Solid Long-Term Potential
by Kinjel Shah
Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 17.74% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Healthcare ETFs, Stocks That Gained Double Digits Last Week
by Sweta Killa
The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.
Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Marinus Pharmaceuticals (MRNS) Soars: Stock Adds 5.5% in Session
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Is the Options Market Predicting a Spike in Marinus (MRNS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Marinus (MRNS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.
Implied Volatility Surging for Marinus (MRNS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.
Marinus Pharmaceuticals (MRNS) Catches Eye: Stock Jumps 7.7%
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) shares rose nearly 8% in the last trading session, amid huge volumes.
Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Marinus (MRNS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Marinus (MRNS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.
Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study
by Zacks Equity Research
Pfizer (PFE) announces failure of a phase III study evaluating Lyrica in patients with primary generalized tonic-clonic seizures, a form of epilepsy.
Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.
Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings
by Zacks Equity Research
Oracle (ORCL) is benefiting from increasing adoption of its product portfolio and synergies from strategic buyouts.
Broadcom (AVGO) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Broadcom (AVGO) extensive product portfolio is likely to positively impact the to-be-reported quarter's results.
Options Traders Expect Huge Moves in Marinus Pharmaceuticals (MRNS) Stock
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) needs investors to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in Marinus Pharmaceuticals (MRNS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.
Marinus Stock Surges on Successful Phase II Epilepsy Study
by Zacks Equity Research
Marinus (MRNS) announced positive top-line data from a phase II study on its epilepsy candidate, ganaxolone, for treating CDKL5 disorder.
Marinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US
by Zacks Equity Research
Marinus Pharmaceuticals, Inc. (MRNS) announced that the FDA has granted orphan drug designation to its key candidate, ganaxolone, for the treatment of adult and pediatric patients with CDKL5 disorder.
Marinus Releases Positive Preliminary Data from CDKL5 Study
by Zacks Equity Research
Marinus Pharmaceuticals, Inc. (MRNS), announced positive preliminary data from the initial CDKL5 pediatric patients enrolled in its ongoing phase II study assessing pipeline candidate, ganaxolone, for the treatment of orphan, genetic disorders.